IP Library › Granted Patent US 12,582,628
Granted Patent B2
US 12,582,628 · App. 17/659,121 · Granted Mar 24, 2026

Methods for treating breast cancer

Inventors: Charles A. Dinarello (Boulder, CO); Isak Tengesdal (Denver, CO)
Assignee: OLATEC THERAPEUTICS, INC.
A61K31/275A61K39/3955A61P35/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,582,628
App. No.
17/659,121
Granted
Mar 24, 2026
Kind
B2
Abstract

The present invention is directed to a method of treating breast cancer. The method comprises administering to a subject in need thereof an effective amount of dapansutrile, or a pharmaceutically acceptable solvate thereof. The method optionally comprises further administering to the subject an effective amount of a checkpoint inhibitor.

Claims (8)

1 . A method of treating breast cancer in a subject, comprising the step of:

administering to a subject in need thereof an effective amount of dapansutrile, or a pharmaceutically acceptable solvate thereof, wherein dapansutrile is administered by oral administration in an amount of 500-4000 mg/day.

2 . The method according to claim 1 , wherein the breast cancer is selected from the group consisting of: ductal carcinoma in situ (DCIS), invasive ductal carcinoma (IDC), triple negative breast cancer (TNBC), inflammatory breast cancer (IBC), metastatic breast cancer, and breast cancer during pregnancy.

3 . The method according to claim 1 , wherein the method reduces the size of the breast tumor.

4 . The method according to claim 1 , wherein the method reduces further growth of the breast tumor.

5 . The method according to claim 1 , further comprising administering to the subject an effective amount of a checkpoint inhibitor.

6 . The method according to claim 5 , wherein the checkpoint inhibitor is an anti-PD-1 antibody.

7 . The method according to claim 1 , wherein the breast cancer is triple negative breast cancer.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 24, 2026
From: DINARELLO, CHARLES A.; TENGESDAL, ISAK
To: OLATEC THERAPEUTICS LLC
Reel/Frame 073876/0754 →
CHANGE OF NAME Recorded Nov 7, 2023
From: OLATEC THERAPEUTICS LLC
To: OLATEC THERAPEUTICS, INC.
Reel/Frame 065489/0809 →
Continuity (3)
Continuation PCTUS2020055219 · Oct 12, 2020
Provisional Application 62914833 · Oct 14, 2019
Related Publication 20220249425A1 · Aug 11, 2022
References Cited (22)
US 9815898B2 · Freeman · 2017 [cited by examiner]
US 10500184B2 · St. Laurent · 2019 [cited by applicant]
US 11576888B2 · Marchetti et al. · 2023 [cited by applicant]
CN 104768553A · 2015 [cited by applicant]
WO 2012082718A2 · 2012 [cited by applicant]
WO 2018129231A1 · 2018 [cited by applicant]
WO 2018129347A1 · 2018 [cited by applicant]
WO 2019152627A1 · 2018 [cited by applicant]
WO 2019032672A1 · 2019 [cited by applicant]
WO 2019182981A1 · 2019 [cited by applicant]
Marchetti, OLT1177, a β-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation, Proc. Natl. Acad. Sci. U.S.A. 115 (7) E1530-E1539 (Year: 2018). [cited by examiner]
Tulotta, C., et al. The role of IL-1B in breast cancer bone metastasis. Endocrine-Related Cancer, 25(7), R421-R434. (Year: 2018). [cited by examiner]
Pensa, S., Stat3 and the Inflammation/Acute Phase Response in Involution and Breast Cancer J Mammary Gland Biol Neoplasia (2009) 14:121-129 (Year: 2009). [cited by examiner]
Marchetti et al, OLT1177,aB-sulfonylnitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation, Proc. Natl. Acad. Sci. U.S.A. 115(7)E1530-E1539 (Year: 2018). [cited by examiner]
Marchetti, Carlo et al., “OLT1177, a β-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation,” Jan. 29, 2018, www.pnas.org/cgi/doi/10.1073/pnas. 17160… [cited by applicant]
Kaplanov et al. “Blocking IL-113 Reverses the Immunosuppression in Mouse Breast Cancer and Synergizes with anti-PD-1 for Tumor Abrogation,” Proceedings of the National Academy of Sciences of the United States of America… [cited by applicant]
United States Patent & Trademark Office (USPTO), International Search Report and Written Opinion, PCT/US2020/8055219, Jan. 19, 2021. [cited by applicant]
European Patent Office (EPO), Extended European Search Report, EP No. 20877745.8, Oct. 17, 2023, corresponding to U.S. Appl. No. 17/659,121. [cited by applicant]
Ershaid, Nour et al., NLRP3 inflammasome in fibroblasts links tissue damage with inflammation in breast cancer progression and metastasis, Nature Communications, Dec. 16, 2018, pp. 1-15, Spring Nature. [cited by applicant]
Kolb, Ryan et al., Inflammasomes in cancer: a doubled-edged sword, Protein & Cell, Jun. 23, 2013, pp. 1-20, Springer. [cited by applicant]
Castaño, Zafira et al., IL-1β inflammatory response driven by primary breast cancer prevents metastasis-initiating cell colonization, Nature Cell Biology, Mar. 21, 2017, pp. 1084-1097, vol. 20, Springer. [cited by applicant]
Tengesdal, Isak W. et al., Activation of Host-NLRP3 Inflammasome in Myeloid Cells Dictates Response to Anti-PD-1 Therapy in Metastatic Breast Cancers, pharmaceuticals, Feb. 22, 2022, vol. 15, issue 5, MDPI Open Access J… [cited by applicant]